Top

02-05-2024 | Fertility | Review

Fertility Preservation in Patients with Breast Cancer

Authors: Emma Manuel, Nicholas S. Raja, Molly Moravek

Published in: Current Breast Cancer Reports

Abstract

Purpose of Review

Many breast cancer treatments are gonadotoxic, which can result in infertility in survivors. Patients should be counseled on the impact of cancer treatment on future fertility and their options regarding fertility preservation. The main purpose of this narrative review is to discuss the implications of breast cancer treatment on future fertility and review various strategies for fertility preservation and their safety in this population.

Recent Findings

There is no demonstrated effect of ovarian stimulation, GnRH agonist therapy, or ovarian tissue cryopreservation/transplantation on breast cancer outcomes. In regard to oocyte/embryo cryopreservation, women should be counseled on equivalent fertilization and pregnancy outcomes with frozen and fresh oocytes/embryos. To prevent delaying the start of neoadjuvant chemotherapy, “random start” protocols can be used and are equally effective as conventional protocols. After breast cancer treatment, women should be counseled on equivalent disease outcomes for those who become pregnant vs. those who do not, including those who interrupt adjuvant endocrine therapy to carry pregnancies.

Summary

Fertility preservation should be discussed and offered to reproductive-aged patients with breast cancer, which has demonstrated safety in this population.

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. https://doi.org/10.1016/j.breast.2022.08.010.CrossRefPubMedPubMedCentral

American Cancer Society. Key statistics for breast cancer. https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html#:~:text=Breast%20cancer%20is%20the%20second,decline%20of%2043%25%20through%202020. Accessed Apr 2023

Ugai T, Sasamoto N, Lee HY, Ando M, Song M, Tamimi RM, Kawachi I, Campbell PT, Giovannucci EL, Weiderpass E, Rebbeck TR, Ogino S. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol. 2022;19(10):656–73. https://doi.org/10.1038/s41571-022-00672-8.CrossRefPubMedPubMedCentral

Rossi L, Mazzara C, Pagani O. Diagnosis and treatment of breast cancer in young women. Curr Treat Options Oncol. 2019;20:86. https://doi.org/10.1007/s11864-019-0685-7.CrossRefPubMed

Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso M-J, Dent RA, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203–17. https://doi.org/10.1016/j.breast.2017.07.017.CrossRefPubMed

Michalczyk K, Cymbaluk-Płoska A. Fertility preservation and long-term monitoring of gonadotoxicity in girls, adolescents and young adults undergoing cancer treatment. Cancers (Basel). 2021;13(2):202. https://doi.org/10.3390/cancers13020202.CrossRefPubMed

Armuand GM, Wettergren L, Rodriguez-Wallberg KA, Lampic C. Desire for children, difficulties achieving a pregnancy, and infertility distress 3 to 7 years after cancer diagnosis. Support Care Cancer. 2014;22:2805–12. https://doi.org/10.1007/s00520-014-2279-z.CrossRefPubMedPubMedCentral

Lehmann V, Keim MC, Nahata L, Shultz EL, Klosky JL, Tuinman MA, Gerhardt CA. Fertility-related knowledge and reproductive goals in childhood cancer survivors: short communication. Hum Reprod. 2017;32:2250–3. https://doi.org/10.1093/humrep/dex297.CrossRefPubMed

Ellis SJ, Wakefield CE, McLoone JK, Robertson EG, Cohn RJ. Fertility concerns among child and adolescent cancer survivors and their parents: a qualitative analysis. J Psychosoc Oncol. 2016;34:347–62. https://doi.org/10.1080/07347332.2016.1196806.CrossRefPubMed

10.

Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32:1151–6.CrossRefPubMedPubMedCentral

11.

Nejatisafa AA, Faccio F, Nalini R. Psychological aspects of pregnancy and lactation in patients with breast cancer. Adv Exp Med Biol. 2020;1252:199–207. https://doi.org/10.1007/978-3-030-41596-9_28.CrossRefPubMed

12.

Ter Welle-Butalid M, Vriens I, Derhaag J, Leter E, de Die-Smulders C, Smidt MM, et al. Counseling young women with early breast cancer on fertility preservation. J Assist Reprod Genet. 2019;36:2593–604. https://doi.org/10.1007/s10815-019-01615-6.CrossRefPubMedPubMedCentral

13.

Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–7. https://doi.org/10.1002/cncr.26459.CrossRefPubMed

14.

Logan S, Perz J, Ussher JM, Peate M, Anazodo A. A systematic review of patient oncofertility support needs in reproductive cancer patients aged 14 to 45 years of age. Psycho Oncol. 2018;27(2):401e9. https://doi.org/10.1002/pon.4502.CrossRef

15.

Kim J, Mersereau JE, Su HI, Whitcomb BW, Malcarne VL, Gorman JR. Young female cancer survivors’ use of fertility care after completing cancer treatment. Support Care Cancer. 2016;24(7):319e9.CrossRef

16.

Sonigo C, Beau I, Binart N, Grynberg M. The impact of chemotherapy on the ovaries: molecular aspects and the prevention of ovarian damage. Int J Mol Sci. 2019;20(21):5342. https://doi.org/10.3390/ijms20215342.CrossRefPubMedPubMedCentral

17.

Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA, Klinger FG. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019;25(6):673–93. https://doi.org/10.1093/humupd/dmz027.CrossRefPubMedPubMedCentral

18.

van Dorp W, Haupt R, Anderson RA, Mulder RL, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Su HI, Winther JF, Hudson MM, Levine JM, Wallace WH. Reproductive function and outcomes in female survivors of childhood, adolescent, and young adult cancer: a review. J Clin Oncol. 2018;36(21):2169–80. https://doi.org/10.1200/JCO.2017.76.3441. Erratum in: J Clin Oncol. 2020;38(8):847.

19.

Oktay K, Briggs D, Gosden RG. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab. 1997;82:3748–51.PubMed

20.

Lambertini M, Marrocco C, Spinaci S, Demeestere I, Anderson RA. Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue. Eur J Clin Invest. 2022;52(7): e13779. https://doi.org/10.1111/eci.13779.CrossRefPubMed

21.

La Marca A, Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol (Oxf). 2006;64(6):603–10. https://doi.org/10.1111/j.1365-2265.2006.02533.x.CrossRefPubMed

22.

Goldfarb SB, Bedoschi G, Grunblatt E, et al. The impact of adjuvant breast cancer (BC) chemotherapy on ovarian reserve and menses. J Clin Oncol. 2015;33:9522.CrossRef

23.

• Goldfarb SB, Turan V, Bedoschi G, Taylan E, Abdo N, Cigler T, Bang H, Patil S, Dickler MN, Oktay KH. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Res Treat. 2021;185(1):165–73. https://doi.org/10.1007/s10549-020-05933-7. This prospective cohort study of women with breast cancer demonstrates a significant negative impact of anthracycline-cyclophosphamide- and cyclophosphamide-methotrexate + 5-fluorouracil-based chemotherapy regimens on ovarian reserve over a 24-month follow-up period. Tamoxifen-only treatment regimens did not alter ovarian reserve.

24.

Gerstl B, Sullivan E, Ives A, Saunders C, Wand H, Anazodo A. Risultati della gravidanza dopo una diagnosi di cancro al seno: una revisione sistematica e una meta-analisi. Carcinoma Mammario Clin. 2018;18:e79–88. https://doi.org/10.1016/j.Clbc.2017.06.016.CrossRef

25.

Razeti MG, Soldato D, Arecco L, Levaggi A, Puglisi S, Solinas C, Agostinetto E, Spinaci S, Lapuchesky L, Genova C, Massarotti C, Lambertini M. Approaches to fertility preservation for young women with breast cancer. Clin Breast Cancer. 2023;23(3):241–8. https://doi.org/10.1016/j.clbc.2023.01.006.CrossRefPubMed

26.

• Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and posttreatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†. Ann Oncol. 2020;31(12):1664–78. https://doi.org/10.1016/j.annonc.2020.09.006. These guidelines provide a framework for fertility preservation in post-pubertal cancer patients. Management flowcharts and a discussion of post-treatment pregnancies in cancer survivors are included.

27.

Anderson RA, Amant F, et al. The ESHRE guideline group on female fertility preservation ESHRE guideline: female fertility preservation†. Hum Reprod Open. 2020;2020(4):hoaa052. https://doi.org/10.1093/hropen/hoaa052.CrossRefPubMedPubMedCentral

28.

Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017;377(17):1657–65. https://doi.org/10.1056/NEJMra1614676.CrossRefPubMed

29.

Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, Mok-Lin E, Chien AJ, Rosen M. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod. 2017;32(10):2123–9. https://doi.org/10.1093/humrep/dex276.CrossRefPubMed

30.

Chen CN, Chang LT, Chen CH, Tam KW. Fertility preservation for women with breast cancer before chemotherapy: a systematic review and meta-analysis. Reprod Biomed Online. 2022;44(2):357–69. https://doi.org/10.1016/j.rbmo.2021.08.003.CrossRefPubMed

31.

Moravek MB, Confino R, Smith KN, Kazer RR, Klock SC, Lawson AK, Gradishar WJ, Pavone ME. Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertil Steril. 2018;109(2):349–55. https://doi.org/10.1016/j.fertnstert.2017.10.029.CrossRefPubMedPubMedCentral

32.

• Marklund A, Eloranta S, Wikander I, Kitlinski ML, Lood M, Nedstrand E, Thurin-Kjellberg A, Zhang P, Bergh J, Rodriguez-Wallberg KA. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study. Hum Reprod. 2020;35(4):929–38. doi: https://doi.org/10.1093/humrep/deaa029. This prospective multicenter study of women with breast cancer demonstrates equal efficacy of letrozole-based and random start protocols compared to conventional controlled ovarian stimulation (COS) protocols. There was no difference in overall survival in women who underwent COS vs. those who did not.

33.

von Wolff M, Bruckner T, Strowitzki T, Germeyer A. Fertility preservation: ovarian response to freeze oocytes is not affected by different malignant diseases—an analysis of 992 stimulations. J Assist Reprod Genet. 2018;35(9):1713–9. https://doi.org/10.1007/s10815-018-1227-0.CrossRef

34.

Lawrenz B, Jauckus J, Kupka M, Strowitzki T, von Wolff M. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril. 2010;94(7):2871–3. https://doi.org/10.1016/j.fertnstert.2010.06.054.CrossRefPubMed

35.

Cobo A, García-Velasco J, Domingo J, Pellicer A, Remohí J. Elective and onco-fertility preservation: factors related to IVF outcomes. Hum Reprod. 2018;33(12):2222–31. https://doi.org/10.1093/humrep/dey321.CrossRefPubMed

36.

Lambertini M, Di Maio M, Pagani O, et al. The BCY3/BCC 2017 survey on physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast. 2018;42:41–9. https://doi.org/10.1016/j.breast.2018.08.099.CrossRefPubMed

37.

Arecco L, Blondeaux E, Bruzzone M, et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod. 2022;37(5):954–68. https://doi.org/10.1093/humrep/deac035.CrossRefPubMedPubMedCentral

38.

• Letourneau JM, Wald K, Sinha N, Juarez-Hernandez F, Harris E, Cedars MI, McCulloch CE, Dolezal M, Chien AJ, Rosen MP. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation. Cancer. 2020;126(3):487–95. https://doi.org/10.1002/cncr.32546. This retrospective study of patients with breast cancer demonstrates no difference in disease-free survival in those who underwent fertility preservation prior to cancer treatment vs. those who did not.

39.

Bonardi B, Massarotti C, Bruzzone M, et al. Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: a systematic review and meta-analysis. Front Oncol. 2020;10. https://doi.org/10.3389/fonc.2020.574669.

40.

Goldrat O, De Cooman M, Mailliez A, Delbaere A, D’Orazio E, Demeestere I, Decanter C. Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: a multicenter retrospective study. Eur J Cancer. 2022;174:134–41. https://doi.org/10.1016/j.ejca.2022.07.017.CrossRefPubMed

41.

Chamayou S, Sicali M, Alecci C, Ragolia C, Liprino A, Nibali D, Storaci G, Cardea A, Guglielmino A. The accumulation of vitrified oocytes is a strategy to increase the number of euploid available blastocysts for transfer after preimplantation genetic testing. J Assist Reprod Genet. 2017;34(4):479–86. https://doi.org/10.1007/s10815-016-0868-0.CrossRefPubMedPubMedCentral

42.

Trokoudes KM, Pavlides C, Zhang X. Comparison outcome of fresh and vitrified donor oocytes in an egg-sharing donation program. Fertil Steril. 2011;95(6):1996–2000. https://doi.org/10.1016/j.fertnstert.2011.02.035.CrossRefPubMed

43.

Turan V, Bedoschi G, Rodriguez-Wallberg K, Sonmezer M, Pacheco FS, Oktem O, Taylor H, Oktay K. Utility of gonadotropin-releasing hormone agonists for fertility preservation: lack of biologic basis and the need to prioritize proven methods. J Clin Oncol. 2019;37(1):84–6. https://doi.org/10.1200/JCO.18.00420.CrossRefPubMed

44.

Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018;36(19):1981–90. https://doi.org/10.1200/JCO.2018.78.0858.CrossRefPubMedPubMedCentral

45.

Li ZY, Dong YL, Cao XZ, Ren SS, Zhang Z. Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis. Menopause. 2022;29(9):1093–100. https://doi.org/10.1097/GME.0000000000002019.CrossRefPubMedPubMedCentral

46.

von Wolff M, Germeyer A, Liebenthron J, Korell M, Nawroth F. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II: fertility preservation techniques. Arch Gynecol Obstet. 2018;297(1):257–67. https://doi.org/10.1007/s00404-017-4595-2.CrossRef

47.

Diaz-Garcia C, Domingo J, Garcia-Velasco JA, et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril. 2018;109(3):478-485.e2. https://doi.org/10.1016/j.fertnstert.2017.11.018.CrossRefPubMed

48.

Gellert SE, Pors SE, Kristensen SG, Bay-Bjørn AM, Ernst E, Yding Andersen C. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018;35(4):561–70. https://doi.org/10.1007/s10815-018-1144-2.CrossRefPubMedPubMedCentral

49.

Donnez J, Dolmans MM, Diaz C, Pellicer A. Ovarian cortex transplantation: time to move on from experimental studies to open clinical application. Fertil Steril. 2015;104(5):1097–8. https://doi.org/10.1016/j.fertnstert.2015.08.005.CrossRefPubMed

50.

Jensen AK, Macklon KT, Fedder J, Ernst E, Humaidan P, Andersen CY. 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children. J Assist Reprod Genet. 2017;34(3):325–36. https://doi.org/10.1007/s10815-016-0843-9. Erratum in: J Assist Reprod Genet. 2017;34(3):337.

51.

Stern CJ, Gook D, Hale LG, Agresta F, Oldham J, Rozen G, Jobling T. First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy. Hum Reprod. 2013;28(11):2996–9. https://doi.org/10.1093/humrep/det360.CrossRefPubMed

52.

Demeestere I, Simon P, Dedeken L, Moffa F, Tsépélidis S, Brachet C, Delbaere A, Devreker F, Ferster A. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod. 2015;30(9):2107–9. https://doi.org/10.1093/humrep/dev128.CrossRefPubMed

53.

Turner KA, Spurlin EE, Jimenez PT. Disparities in female oncofertility care in the United States: more questions than answers. Life (Basel). 2023;13(7):1547.PubMed

54.

National Public Health Plan. Available at https://www.cdc.gov/reproductivehealth/infertility/pdf/drh_nap_final_508.pdf. Accessed 24 April 2022.

55.

Kelley AS, et al. Disparities in accessing infertility care in the United States: results from the National Health and Nutrition Examination Survey, 2013–2016. Fertil Steril. 2019;112(3):562–8.CrossRefPubMed

56.

Missmer SA, Seifer DB, Jain T. Cultural factors contributing to health care disparities among patients with infertility in Midwestern United States. Fertil Steril. 2011;95:1943–9.CrossRefPubMed

57.

Goodman LR, Balthazar U, Kim J, Mersereau JE. Trends of socioeconomic disparities in referral patterns for fertility preservation consultation. Hum Reprod. 2012;27:2076–81.CrossRefPubMedPubMedCentral

58.

Zebrack B. Information and service needs for young adult cancer survivors. Support Care Cancer. 2009;17:349–57.CrossRefPubMed

59.

Resolve.org. Insurance coverage by state. https://resolve.org/learn/financial-resources-for-family-building/insurance-coverage/insurance-coverage-by-state/. Updated September 2023. Accessed 23 Jan 2024.

60.

Mobley EM, Ryan GL, Sparks AE, Monga V, Terry WW. Factors Impacting fertility preservation in adolescents and young adults with cancer: a retrospective study. J Adolesc Young Adult Oncol. 2020;9:208–21.CrossRefPubMedPubMedCentral

61.

Livestrong.org. Livestrong fertility. https://www.livestrong.org/what-we-do/program/fertility. Accessed 23 Jan 2024.

62.

Letourneau JM, Smith JF, Ebbel EE, Craig A, Katz PP, Cedars MI, Rosen MP. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer. 2012;118:4579–88.CrossRefPubMed

63.

Quinn GP, Vadaparampil ST, Gwede CK, Miree C, King LM, Clayton HB, Wilson C, Munster P. Discussion of fertility preservation with newly diagnosed patients: oncologists’ views. J Cancer Surviv. 2007;1:146–55.CrossRefPubMed

64.

Forman EJ, Anders CK, Behera MA. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril. 2010;94:1652–6.CrossRefPubMed

65.

Saraf AJ, Stanek J, Audino A, DaJusta D, Hansen-Moore J, McCracken K, Whiteside S, Yeager N, Nahata L. Examining predictors and outcomes of fertility consults among children, adolescents, and young adults with cancer. Pediatr Blood Cancer. 2018;65: e27409.CrossRefPubMed

66.

Banerjee R, Tsiapali E. Occurrence and recall rates of fertility discussions with young breast cancer patients. Support Care Cancer. 2016;24(1):163–71. https://doi.org/10.1007/s00520-015-2758-x.CrossRefPubMed

67.

Srikanthan A, Amir E, Warner E. Does a dedicated program for young breast cancer patients affect the likelihood of fertility preservation discussion and referral? Breast. 2016;27:22–6. https://doi.org/10.1016/j.breast.2016.02.012.CrossRefPubMed

68.

Di Mattei VE, Perego G, Taranto P, Mazzetti M, Ferrari F, Derna N, Peccatori FA, Mangili G, Candiani M. Psychological issues in breast cancer survivors confronted with motherhood: literature review and a call to action. Front Psychol. 2023;2(14):1133204. https://doi.org/10.3389/fpsyg.2023.1133204.CrossRef

69.

Schmidt R, Richter D, Sender A, Geue K. Motivations for having children after cancer—a systematic review of the literature. Eur J Cancer Care. 2016;25:6–17. https://doi.org/10.1111/ecc.12276.CrossRef

70.

Raphael J, Trudeau ME, Chan K. Outcome of patients with pregnancy during or after breast cancer: a review of the recent literature. Curr Oncol. 2015;22(Suppl 1):S8–18. https://doi.org/10.3747/co.22.2338.CrossRefPubMedPubMedCentral

71.

•• Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645–56. https://doi.org/10.1056/NEJMoa2212856. This prospective study evaluates the temporary interruption of adjuvant endocrine therapy in breast cancer patients who desire to attempt pregnancy. Results demonstrate no difference in short-term risk of breast cancer events, including distant recurrence, compared to an external control cohort.

72.

• Condorelli M, De Vos M, Lie Fong S, Autin C, Delvigne A, Vanden Meerschaut F, Wyns C, Imbert R, Cheruy C, Bouziotis J, de Azambuja E, Delbaere A, Lambertini M, Demeestere I. Impact of ARTs on oncological outcomes in young breast cancer survivors. Hum Reprod. 2021;36(2):381–89. https://doi.org/10.1093/humrep/deaa319. This retrospective multicentric matched cohort study demonstrates no negative impact of assisted reproductive technology (ART) on disease-free survival in breast cancer survivors.

73.

Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril. 2005;83(6):1622–28. https://doi.org/10.1016/j.fertnstert.2005.03.013

74.

Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, Wallace WH, Wang ET, Loren AW. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001. https://doi.org/10.1200/JCO.2018.78.1914.CrossRefPubMed

Title: Fertility Preservation in Patients with Breast Cancer
Authors: Emma Manuel
Nicholas S. Raja
Molly Moravek
Publication date: 02-05-2024
Publisher: Springer US
Keywords: Fertility
Breast Cancer
Breast Cancer
GnRH Agonists
Infertility
Infertility
Published in: Current Breast Cancer Reports
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-024-00551-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer